FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387206359> ?p ?o ?g. }

• W4387206359 endingPage "e138" @default.
• W4387206359 startingPage "e138" @default.
• W4387206359 abstract "Patients (pts) with advanced lung cancer often receive combined palliative thoracic radiotherapy (RT) and immune checkpoint inhibitors (ICI). There are limited data assessing the toxicities of combined ICI-RT in this setting. We sought to compare the rates of clinically significant pneumonitis among pts with lung cancer receiving palliative thoracic RT with or without recent or concomitant ICI. We hypothesized there would be a higher rate of grade 2+ pneumonitis among RT pts who received recent or concomitant ICI compared to those who did not.We retrospectively identified consecutive pts with advanced/recurrent lung cancer from a tertiary academic center who received palliative thoracic RT with recent (defined as within 95 days of RT start) or concomitant ICI (ICI-RT group) between January 2014 and February 2020. Pts were propensity matched in a 1:1 manner (by age, sex, ECOG, RT modality, and RT dose) to lung cancer pts who received palliative thoracic RT without any history of ICI receipt (RT-only group). The presence and grade (CTCAE v5.0) of pneumonitis were independently assessed by two investigators. The primary endpoint was grade 2+ pneumonitis, estimated using the cumulative incidence function and compared between the ICI-RT and RT-only groups using Gray's test. The secondary endpoint was overall survival, estimated using the Kaplan-Meier method and compared between groups using the log-rank test.A total of 146 pts were included in the study (73 in each group). There were no statistically significant differences between the ICI-RT and RT-only groups with respect to age (median 67.7 vs. 67.6, p = 0.97), sex (52% vs. 52% female, p = 1.00), pre-treatment ECOG 0-1 (74% vs 75%, p = 0.85), or biologically effective dose greater than 45 (48% vs. 48%, p = 1.00). The most common RT regimens were 30 Gy in 10 fractions (33 pts, 23%) and 20 Gy in 5 fractions (18 patients, 12%). A plurality of cases utilized 3DCRT (67 pts, 46%). In the ICI-RT group, the median time from last dose of ICI to the start of palliative RT was 16 days; three pts in this group-initiated ICI while receiving RT treatment. The most common ICI was pembrolizumab (36 pts, 49%). A total of eleven grade 2+ pneumonitis events (nine grade 2 and two grade 3 events) were observed. The ICI-RT group had a higher cumulative incidence of grade 2+ pneumonitis compared with the RT-only group (1-year rate, 12.3% vs. 2.7%, p = 0.029); grade 3 pneumonitis occurred in 1/73 (1.4%) in each group. There was no difference in overall survival between groups (median 239 vs. 218 days, p = 0.76).In pts with advanced lung cancer treated with palliative thoracic RT, recent or concomitant ICI use was associated with a higher cumulative incidence of grade 2+ pneumonitis. However, the incidence of grade 3+ pneumonitis was low (1.4%) regardless of ICI receipt." @default.
• W4387206359 created "2023-09-30" @default.
• W4387206359 creator A5015582820 @default.
• W4387206359 creator A5035208282 @default.
• W4387206359 creator A5036806498 @default.
• W4387206359 creator A5046322160 @default.
• W4387206359 creator A5052066127 @default.
• W4387206359 creator A5067536094 @default.
• W4387206359 creator A5070392597 @default.
• W4387206359 creator A5084574866 @default.
• W4387206359 creator A5090230371 @default.
• W4387206359 creator A5090256464 @default.
• W4387206359 date "2023-10-01" @default.
• W4387206359 modified "2023-10-17" @default.
• W4387206359 title "Pneumonitis after Palliative Thoracic Radiotherapy +/- Immunotherapy: A Retrospective Propensity-Matched Cohort Study" @default.
• W4387206359 doi "https://doi.org/10.1016/j.ijrobp.2023.06.945" @default.
• W4387206359 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37784706" @default.
• W4387206359 hasPublicationYear "2023" @default.
• W4387206359 type Work @default.
• W4387206359 citedByCount "0" @default.
• W4387206359 crossrefType "journal-article" @default.
• W4387206359 hasAuthorship W4387206359A5015582820 @default.
• W4387206359 hasAuthorship W4387206359A5035208282 @default.
• W4387206359 hasAuthorship W4387206359A5036806498 @default.
• W4387206359 hasAuthorship W4387206359A5046322160 @default.
• W4387206359 hasAuthorship W4387206359A5052066127 @default.
• W4387206359 hasAuthorship W4387206359A5067536094 @default.
• W4387206359 hasAuthorship W4387206359A5070392597 @default.
• W4387206359 hasAuthorship W4387206359A5084574866 @default.
• W4387206359 hasAuthorship W4387206359A5090230371 @default.
• W4387206359 hasAuthorship W4387206359A5090256464 @default.
• W4387206359 hasConcept C10515644 @default.
• W4387206359 hasConcept C126322002 @default.
• W4387206359 hasConcept C141071460 @default.
• W4387206359 hasConcept C143998085 @default.
• W4387206359 hasConcept C159110408 @default.
• W4387206359 hasConcept C167135981 @default.
• W4387206359 hasConcept C203092338 @default.
• W4387206359 hasConcept C2776256026 @default.
• W4387206359 hasConcept C2777714996 @default.
• W4387206359 hasConcept C2779384505 @default.
• W4387206359 hasConcept C2779524853 @default.
• W4387206359 hasConcept C2994186709 @default.
• W4387206359 hasConcept C509974204 @default.
• W4387206359 hasConcept C535046627 @default.
• W4387206359 hasConcept C66339696 @default.
• W4387206359 hasConcept C71924100 @default.
• W4387206359 hasConcept C72563966 @default.
• W4387206359 hasConcept C88879693 @default.
• W4387206359 hasConceptScore W4387206359C10515644 @default.
• W4387206359 hasConceptScore W4387206359C126322002 @default.
• W4387206359 hasConceptScore W4387206359C141071460 @default.
• W4387206359 hasConceptScore W4387206359C143998085 @default.
• W4387206359 hasConceptScore W4387206359C159110408 @default.
• W4387206359 hasConceptScore W4387206359C167135981 @default.
• W4387206359 hasConceptScore W4387206359C203092338 @default.
• W4387206359 hasConceptScore W4387206359C2776256026 @default.
• W4387206359 hasConceptScore W4387206359C2777714996 @default.
• W4387206359 hasConceptScore W4387206359C2779384505 @default.
• W4387206359 hasConceptScore W4387206359C2779524853 @default.
• W4387206359 hasConceptScore W4387206359C2994186709 @default.
• W4387206359 hasConceptScore W4387206359C509974204 @default.
• W4387206359 hasConceptScore W4387206359C535046627 @default.
• W4387206359 hasConceptScore W4387206359C66339696 @default.
• W4387206359 hasConceptScore W4387206359C71924100 @default.
• W4387206359 hasConceptScore W4387206359C72563966 @default.
• W4387206359 hasConceptScore W4387206359C88879693 @default.
• W4387206359 hasIssue "2" @default.
• W4387206359 hasLocation W43872063591 @default.
• W4387206359 hasLocation W43872063592 @default.
• W4387206359 hasOpenAccess W4387206359 @default.
• W4387206359 hasPrimaryLocation W43872063591 @default.
• W4387206359 hasRelatedWork W1971557041 @default.
• W4387206359 hasRelatedWork W2047967234 @default.
• W4387206359 hasRelatedWork W2086634131 @default.
• W4387206359 hasRelatedWork W2106653639 @default.
• W4387206359 hasRelatedWork W2353103559 @default.
• W4387206359 hasRelatedWork W2407189953 @default.
• W4387206359 hasRelatedWork W2889084562 @default.
• W4387206359 hasRelatedWork W3014330536 @default.
• W4387206359 hasRelatedWork W4221070417 @default.
• W4387206359 hasRelatedWork W4308463093 @default.
• W4387206359 hasVolume "117" @default.
• W4387206359 isParatext "false" @default.
• W4387206359 isRetracted "false" @default.
• W4387206359 workType "article" @default.